# EDGAR Filing Document

**Accession Number:** 0001492074
**File Stem:** 0001193125-23-066775
**Filing Date:** 2023-3
**Character Count:** 5548
**Document Hash:** 713c57e6b1b5432ffb32cd738fc3419b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-066775.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001193125-23-066775

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Abcam plc
- **CENTRAL INDEX KEY:** 0001492074
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 980487031
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39633
- **FILM NUMBER:** 23721617

**BUSINESS ADDRESS:**
- **STREET 1:** DISCOVERY DRIVE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AX
- **BUSINESS PHONE:** 44(0)1223696000

**MAIL ADDRESS:**
- **STREET 1:** DISCOVERY DRIVE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AX

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Abcam PLC
- **DATE OF NAME CHANGE:** 20100514

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of March 2023** 

**Commission File Number: 001-39633** 

------

## Abcam plc
**(Translation of registrant's name into English)** 

------

**Discovery Drive** 

**Cambridge Biomedical Campus** 

**Cambridge, CB2 0AX** 

**United Kingdom** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K** 

On March 10, 2023, Abcam plc (the "<u>Company</u>") issued a news service announcement (the "<u>Announcement</u>") announcing its plans to update the market on March 20, 2023 with its full year results for the year ended December 31, 2022. The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Announcement dated March 10, 2023](d450480dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **ABCAM PLC** | **ABCAM PLC** | **ABCAM PLC** |
| Date: March 10, 2023 | By: | /s/ Alan Hirzel | /s/ Alan Hirzel |
|  |  | Name: | Alan Hirzel |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**ABCAM PLC** 

**Abcam to Report Full Year Results on Monday, March 20, 2023** 

10, March 2023, Cambridge, UK—Abcam plc (Nasdaq: ABCM) ("**Abcam**" or the "**Company**"), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m. ET on 20 March 2023.

Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. ET that same day (details below).

To access the webcast, please use the following link:

<u>https://events.q4inc.com/earnings/LONABC/FY22</u> 

The press release and the live audio webcast will also be available in the investor section of Abcam's corporate website at <u>corporate.abcam.com/investors/reports-presentations/</u>. An archive will be available after the call at that same address.

For further information please contact:

---

| | |
|:---|:---|
| **Abcam** | +1 617 577 4205 |
| Tommy Thomas, CPA, Vice President, Investor Relations |  |

---

**About Abcam plc** 

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit <u>www.abcam.com</u> or <u>www.abcamplc.com</u>